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Abstract 
 
THE EFFECT OF E-CADHERIN LOSS ON MELANOMA FORMATION AND 
METASTASIS. 
Lara E. Rosenbaum, William Damsky, Katrina Meeth, and Marcus 
Bosenberg.  Department of Dermatology, Yale University School of 
Medicine, New Haven, CT.  
 
Melanoma is the most lethal form of skin cancer and accounts for the 
majority of skin cancer related mortality.  Early metastases are 
characteristic of melanoma and are an ominous sign, as current 
therapeutic interventions have little effect on overall survival.  The lack of 
accurate prognostic indicators and effective therapies emphasize the 
need for a better understanding of the genetic and phenotypic changes 
in melanoma formation and progression.  One such change is the loss of 
E-cadherin, which normally plays a role in cell-cell adhesion and is thought 
to be a central feature of epithelial-mesenchymal transition (EMT).  
Maintenance of E-cadherin in melanoma may function to restrict 
melanoma invasion, and loss of E-cadherin expression is associated with 
mesenchymal features and melanoma metastasis.  While several studies 
have suggested that loss of E-cadherin is associated with cancer 
progression, functional evaluation of the effects of E-cadherin loss on 
metastasis has not been well established. 
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In order to evaluate these important issues on the role of E-cadherin in 
melanoma formation and metastasis, we have utilized a well-
characterized conditional mouse model combining the activating Braf 
V600E mutation with Pten tumor suppressor loss (Braf/Pten tumor model).  
This model allows us to alter these genes in mouse melanocytes in a 
spatially and temporally restricted manner, producing melanoma 
specifically and reproducibly.  We have combined this model with 
conditional E-cadherin inactivation in order to evaluate the role of E-
cadherin loss on melanoma formation, progression and metastasis as well 
as changes in cell morphology and signaling.  Loss of E-cadherin 
significantly decreases survival of mice in the Braf/Pten tumor model 
(p=0.024) and alters the expression of markers of EMT as demonstrated by 
RNA microarray analysis.  Surprisingly, no difference in metastases to either 
the lymph nodes (p=0.28) or lungs (p=0.39) are seen with loss of E-
cadherin.   
 
Additionally, Braf activation in combination with E-cadherin loss 
(Braf/Ecad model) leads to melanoma in 100% of mice with tumor death 
occurring after an average of 302 days (range: 199 – 395 days) or 
approximately 10 months.  This novel model is in striking contrast to the 
Braf/Pten tumor model, which has an average lifespan of 40 days.  No 
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tumors develop in mice with Braf activation alone or E-cadherin loss alone 
nor in mice with both loss of E-cadherin and loss of Pten.  The Braf/Ecad 
tumor model shows activation of mammalian target of rapamycin (mTOR) 
signaling, a commonly dysregulated protein in human cancers, as well as 
activity in the P13K/Akt pathway which regulates cellular proliferation and 
survival.  Some markers of EMT are also upregulated in the Braf/Ecad 
tumor model. 
 
These findings functionally delineate the role of E-cadherin loss in 
melanoma formation, metastasis and EMT.  Additional evidence is 
garnered which supports the role of E-cadherin as a tumor suppressor 
gene and that its loss is functionally important in altering key pathways of 
cellular growth and survival.  With better understanding of melanoma, 
new treatments will be developed to help manage this devastating 
cancer.   
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Introduction 
MELANOMA 
Importance of Melanoma 
Melanoma is a common cancer arising from melanocytes, the pigment-
forming cells of the skin.  Given its aggressive nature and increasing 
incidence, research to further understand melanoma formation and 
metastasis is important for improving human health.  It is estimated that 
76,250 cases of melanoma and 9,180 deaths due to melanoma will occur 
in 2012, making it the fifth and sixth most common cancer diagnosed in 
men and women, respectively (1).  In fact, 1 in 36 men and 1 in 55 women 
will develop melanoma during the course of a lifetime (1).  Unfortunately, 
as the incidence rate is increasing by >2% per year in the white 
population, melanoma continues to be of significant concern (2).  
 
If melanoma is recognized and diagnosed early, treatment may involve 
simple local excision with greater than 90% survival at 10 years for patients 
with melanomas less than 1.00 mm thick (3).  However, once melanoma 
has metastasized, it is challenging to treat and prognosis is poor.  At best, 
one-year survival in this group is 62% (based on location of melanoma 
spread); at worst, one-year survival can be as low as 33% (3).  Despite the 
increasing incidence of melanoma, the death rate due to melanoma has 
remained essentially stable over the last 20 years (4). 
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Therapeutic Advances 
Recent advances in immunomodulatory therapies and targeted therapies 
has led to Food and Drug Administration (FDA) approval of two new 
treatments for melanoma in 2011.  These novel therapies are the first to be 
approved for melanoma treatment in the last 13 years.   
 
The first, ipilimumab, is a monoclonal antibody that blocks cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4).  Blocking of CTLA-4 leads to 
enhancement of antitumor activity.  While survival continues to be poor in 
patients with metastatic melanoma, treatment with ipilimumab can lead 
to prolonged survival in approximately 20% of patients (compared to 
<10% without ipilimumab) (5) (6).   
 
The second new treatment is vemurafenib (also known as PLX4032), a 
small molecule inhibitor of mutant Braf.  Braf, an intracellular protein 
important in pathways affecting cell division, is mutated in approximately 
50% of human melanomas (7) (see next section: Melanoma Genetics).  In 
patients treated with vemurafenib, there is a 6-month survival of 84%, 
compared to 64% at 6 months in patients treated with dacarbazine (a 
standard chemotherapeutic agent) (7).  Though both of these therapies 
show exceptional promise and are making a clear impact on patient 
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lives, more work is needed to both better understand and treat this lethal 
disease.   
 
Melanoma Genetics 
Much work has been completed in recent years to assess commonly 
mutated genes in melanoma with the hopes of better understanding this 
deadly disease and developing improved therapeutics.  As discussed 
above (see previous section: Therapeutic advances), Braf is mutated in 
about 50% of human melanomas (7) leading to constitutive activation of 
the mitogen activated protein kinase (MAPK) pathway.  Activation of this 
pathway leads to increased cellular proliferation.  Confirmation of mutant 
Braf as an activating oncogenic mutation has been confirmed in several 
studies, including in a mouse model developed by the Bosenberg lab (8).   
 
Also commonly deregulated in melanoma are proteins in the 
phosphoinositide 3-kinase (PI3K) / Akt pathway, which also regulates 
cellular proliferation and survival.  Within this pathway is the phosphatase 
and tensin homologue (Pten), which inhibits activation of the PI3K/Akt 
pathway.  Inversely, loss of the tumor suppressor Pten leads to activation 
of the pathway.  Unlike Braf, Pten is only mutated in approximately 5% of 
melanomas; however, expression is lost in up to 50% of melanomas (9) 
(10).  Like Braf, this mutation has been shown to be functionally important 
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in melanoma formation and progression by the Bosenberg lab (8).  
Additionally, activation of the PI3K/Akt pathway leads to activation of 
mammalian target of rapamycin (mTOR) signaling, which consists of two 
protein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 
(mTORC2).  mTOR signaling is important for a myriad of processes related 
to cellular metabolism and is commonly dysregulated in cancer (11). 
 
E-CADHERIN 
E-cadherin Function 
E-cadherin is a cell-cell adhesion protein that is part of a family of proteins 
called cadherins.  The classic cadherins, which includes E-cadherin, are 
calcium-dependent homophilic molecules that can be found throughout 
the human body (12).  E-cadherin was named due to its predominance in 
epithelial tissues in which it forms the adherens junction.  It is expressed on 
keratinocytes as well as melanocytes and is functionally important in the 
interaction of these cells (13).  Other cadherins include N-cadherin (neural 
cadherin), P-cadherin (placental cadherin) and R-cadherin (retinal 
cadherin), though many other classical cadherins have also been 
identified.   
 
E-cadherin is a single pass transmembrane protein.  The extracellular 
domain consists of five cadherin-type repeats that in conjunction with 
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calcium form a rod-like structure.  The 3-D configuration of these 
extracellular domains within an adhesive cell-cell homophilic bond 
remains unclear, though several models have been proposed (12).  The 
intracellular interactions and functions of E-cadherin have also been well 
studied.   E-cadherin is attached to the actin cytoskeleton through an 
interaction with α-catenin and β-catenin.  Additional proteins (p120, 
formin-1, vinculin and α-actinin) also interact with E-cadherin intracellularly 
and may play a role in actin-binding or other cell-signaling functions (12).  
 
Importance of E-cadherin in Cancer Biology 
Germline mutations in E-cadherin lead to hereditary diffuse gastric cancer 
(HDGC), an autosomal dominant cancer syndrome.  In patients with E-
cadherin mutations, >80% will develop advanced gastric cancer by 80 
years of age; thus, prophylactic gastrectomy is typically offered at age 20 
when the risk of cancer development is still quite low (14).  While no 
dominant mutation has been identified in CDH1 (the gene for E-cadherin), 
over 100 mutations have been identified in unrelated families of varying 
countries of origin (15).  Diffuse gastric cancer begins to develop in these 
patients when the second (normal) copy of E-cadherin is either 
inactivated, dowregulated (often through promoter hypermethylation) or 
lost (15), suggesting a role for E-cadherin as a tumor suppressor (see next 
section: E-cadherin as Tumor Suppressor).   Additionally, women with this 
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mutation have a significantly increased risk of developing lobular breast 
cancer (60% by age 80) and screening for breast cancer typically begins 
by age 35 (14).  
 
Apart from HDGC, E-cadherin is also lost or downregulated in numerous 
human cancers in individuals with normal E-cadherin in the rest of their 
tissues.  E-cadherin has shown to be downregulated in many cancers, 
including head and neck squamous cell carcinomas, lobular breast 
carcinoma, colorectal carcinoma, gastric carcinomas, prostate 
carcinoma, lung carcinoma, thyroid carcinoma, hepatocellular 
carcinoma, bladder carcinoma, and melanoma (16), (17).  While for 
many of these cancers, it is thought that loss of E-cadherin leads to a 
poorer prognosis (compared to intact E-cadherin expression), this 
relationship has sometimes been difficult to conclusively establish in many 
of these cancers, including in melanoma (17).   
 
E-cadherin as Tumor Suppressor: Activation of the PI3K/Akt Pathway 
As discussed in the previous section, one of the strongest suggestions that 
E-cadherin functions as a tumor suppressor is the discovery that germline 
mutations lead to an autosomal dominant cancer syndrome.  Indirectly, 
loss of E-cadherin, either through mutations, loss of heterozygosity, or 
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hypermethylation, is noted in many human cancers, implicating a key role 
in cancer development (18).   
 
Many recent studies have utilized cancer cell lines to demonstrate a 
relationship between loss of E-cadherin and activation of the PI3/Akt 
pathway (19) (20) (21).  In Lau et al., the authors used ovarian cancer cell 
lines and were able to show that loss of E-cadherin leads to 
phosphorylation (and thus activation) of Akt as well as increased cellular 
growth.  They showed some evidence that this activation was due to β-
catenin inhibiting early growth response gene 1 (Egr1), which in turn 
downregulated Pten (19).   
 
Not all studies have implicated β-catenin as the key mediator of Pten 
downregulation by E-cadherin.  In Li et al., researchers used breast 
carcinoma cell lines to investigate the relationship between E-cadherin 
and Pten.  They were able to show that both loss of E-cadherin and 
disruption of E-cadherin cell-cell adhesion leads to decreased levels of 
intracellular Pten (21).  These findings suggest that activation of the 
PI3K/Akt pathway due to loss of E-cadherin is not due exclusively to β-
catenin.   
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Finally, Fournier et al. were able to show that loss of E-cadherin activated 
the PI3K/Akt pathway in normal breast epithelial cell lines also via 
downregulation of Pten.  By treating these cell lines with an E-cadherin 
blocking antibody, these researchers were able to show an approximately 
30% decrease in intracellular Pten.  This finding correlated with increased, 
disorganized cell growth (20).   
 
EPITHELIAL-MESENCHYMAL TRANSITION (EMT) 
History of EMT 
In order to understand EMT, it is important to first understand the tissue 
types being discussed.  An epithelium consists of cells with apical-basal 
polarity, strong cell-cell contacts, low motile capacity and which typically 
perform a secretory or barrier role.  Mesenchymal cells, on the other hand, 
have front-back polarity or no polarity, are spindle-shaped, have few cell-
cell contacts, are highly motile and may perform scaffolding or anchoring 
roles (22), (23).  The concept of EMT was first described by RL Trelstad, JP 
Revel and ED Hay in 1966 while investigating chick embryogenesis to 
explain the formation of mesoderm (mesenchymal tissue) from ectoderm 
(an epithelium) in the embryo (24) (25).  EMT occurs most clearly during 
gastrulation and neural crest cell formation.  In gastrulation, some cells of 
the ectoderm begin to ingress and take on more mesenchymal features, 
eventually becoming the mesoderm (23).   Further in embryogenesis, the 
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neural tube will form and begin to close.  At the time of closing or just 
after, cells from the neural ectoderm undergo an EMT to form neural crest 
cells (26).  Neural crest cells give rise to many cell types in the complete 
embryo, including neurons, Schwann cells and melanocytes (26).  
 
Expression of many proteins is altered during the course of an EMT in 
embryogenesis.  Studies have shown that E-cadherin, which is highly 
expressed in epithelial tissues, is lost and N-cadherin is upregulated (26).  
This phenomenon is frequently termed “cadherin switching.”  Vimentin, a 
cytoskeletal protein, and fibronectin, an extracellular glycoprotein, are 
also upregulated (27), (28).  Snail, Slug, Twist and Zeb1, transcription 
factors that repress transcription of the gene for E-cadherin, are 
upregulated (26), (27).  Additional markers of EMT have also been 
described (28). 
 
EMT in Cancer Biology 
The acquisition of mesenchymal traits by epithelial cancer cells during the 
process of tumor invasion and metastasis has been a subject of intense 
interest recently.  This process has several features of epithelial 
mesenchymal transitions (EMT) described in developmental biology 
studies (29).  Loss of E-cadherin expression and increased expression of 
members of the Twist family of zinc finger transcription factors are key 
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features of EMT.  While several studies have demonstrated that expression 
of mesenchymal markers is associated with progression of many cancers, 
functional evaluation of the effects of altering the characteristic features 
of EMT on metastasis has not been well established.   
 
The majority of studies establishing the existence of EMT in cancer biology 
have used in vitro assays (28).  These assays have demonstrated changes 
in cell morphology, a loss of cell polarization, increased cell matrix 
interactions, increased motility, and resistance to anoikis (a form of 
programmed cell death), which all suggest a loss of epithelial features 
and a gain of mesenchymal cell characteristics.  These assays suggest an 
EMT has occurred and are consistent with acquisition of increased 
invasive capabilities. 
 
Despite clear in vitro evidence, the in vivo evidence for EMT has been 
somewhat more controversial (30).  On one hand, a xenograft study using 
human cell lines in immunocompromised mice showed that loss of E-
cadherin in immortalized human breast epithelial cells resulted in 
increased mesenchymal features and a more invasive and metastatic 
phenotype when subcutaneously injected into mice (31).  Other studies in 
mouse models have found that when metastases of cells expected to 
have undergone EMT were analyzed, they resembled epithelial cells more 
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than mesenchymal cells.  This suggests that if an EMT had occurred it must 
have been followed by a mesenchymal to epithelial cell transition (MET) 
once the cells seeded the target organ (32).  One hypothesis to explain 
this phenomenon is that in the absence of a microenvironment inducing 
EMT, the cells revert to their baseline epithelial state (33).  Still other studies 
have suggested that cells in vivo may actually exhibit a more hybrid 
epithelial-mesenchymal phenotype compared to the more complete EMT 
seen in vitro (28).  As stated above, the most convincing evidence for EMT 
has been established in an in vitro environment.  This environment is highly 
artificial, lacking the complex cell-cell interactions in a three-dimensional 
space with no vascular, neurologic, or endocrine input.  Additionally, if 
EMT were so critical to cancer metastasis, one would expect this to be 
readily apparent on histopathologic examination of human cancers sent 
for diagnosis.  This, however, is not typically seen, and in fact, most 
invasive carcinomas are readily recognizable as of epithelial lineage (30).  
 
Despite these controversies in the literature about EMT, many feel that E-
cadherin loss is a central feature of EMT and is associated with cancer 
progression (34).  E-cadherin loss has also been documented in 
melanoma and is frequently associated with increased N-cadherin 
expression (35).  Downregulation of E-cadherin in human melanoma may 
occur by several mechanisms, including promoter hypermethylation (36), 
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or repression by Snail, Slug, Zeb-1, or Tbx3 transcription factors (28).  While 
the correlation of E-cadherin downregulation in cancer has been 
established, it is not clear how much of the EMT phenotype is due to E-
cadherin loss and what the effect of E-cadherin loss is on metastasis.   
 
A MOUSE MODEL OF MELANOMA 
In order to address important questions in melanoma formation and 
metastasis, a novel mouse model has been developed to investigate 
specific genetic hits within the melanocytes of mice.  These novel mouse 
models are based on a transgenic mouse line that was previously 
generated and characterized in which expression of a Cre recombinase-
estrogen receptor fusion protein is expressed under the melanocyte-
specific tyrosinase promoter (Tyr::CreERT) (37).  In brief, inducible 
recombination of target genes containing lox sites that flank a DNA 
sequence to be excised is efficiently induced by topical 4-
hydroxytamoxifen (4-HT) application in a spatially and temporally 
restricted manner.  Following the demonstration of functionality of the 
Tyr::CreERT lines, lox knock-in lines of genes relevant to human melanoma 
were acquired including Braf, Pten, and E-cadherin.   
 
The Braf ser/thr kinase is the most commonly mutated gene known in 
human melanoma, with about 60% of the most common forms of 
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melanoma containing activating mutations of Braf (usually Braf V600E) 
(38).  Martin McMahon's laboratory at UCSF has generated a knock-in 
allele of activated Braf (BrafCA) that is phenotypically wild type until Cre-
mediated recombination produces an allele (Braf V600E) that contains 
the V600E point mutation and retains a single intronic 34bp loxP site, but 
otherwise resembles the wild type chromosome exactly (8).  
 
The Pten tumor suppressor undergoes promoter hypermethylation and 
reduction of expression in roughly 30% of melanomas, but is only mutated 
in 5% of melanomas (10). We acquired a Pten allele from Ron DePinho 
and James You in which exon 5 is flanked by lox sites (8). 
 
E-cadherin is commonly downregulated in human melanoma with 
variable levels of expression.  While difficult to quantify, there is a trend 
towards poorer prognosis in those melanomas with less expression of E-
cadherin (17).  The Bosenberg lab has acquired an E-cadherin allele with 
lox sites that upon recombination leads to loss of exons 6 – 10 (39).  
 
The Bosenberg lab has generated and analyzed 4-HT-treated cohorts of 
the genetic hits individually and in many combinations.  All of the 
inductions of genetic recombination in these experiments were performed 
with a relatively high concentration of topical 4-HT (50 mg/ml in DMSO) 
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applied to the mouse on days 3, 5, and 7 of life and resulted in 
generalized/systemic recombination of lox-containing alleles specifically 
in melanocytes.  Activation of Braf in melanocytes results in a mild 
melanocytic hyperplasia/nevus formation (8), although tumor formation 
has been noted using a similar mouse model (40).  None of the other 
individual genetic hits listed above have a clearly altered melanocytic 
phenotype.  In contrast, combinations of particular genetic hits have 
produced some of the most interesting tumorigenic and metastatic 
phenotypes described in any mouse model to date. 
 
Activation of Braf combined with loss of Pten produces a dramatic 
phenotype (Braf/Pten tumor model).  Following induction of 
recombination on days 3, 5, and 7 of life, widespread pigmented 
melanocytic proliferations are evident within days; pups are uniformly 
darkly pigmented within 12 days; nodular growths are evident within 15 
days, and the mice need to be euthanized shortly after weaning (~30 
days) secondary to decreased motility, failure to thrive, and the 
observation of occasional death of littermates with similar behavioral 
changes (8).  All of the mice have multiple lymph node metastases, many 
of which have shown evidence of growth within the lymph node with 
partial to near-complete lymph node replacement.  In addition, several 
lung metastases are also typically noted within the two to three week 
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span of this experiment (8).  The Bosenberg lab has also optimized local 
induction protocols in Tyr::CreERT Braf/Pten mice that result in melanoma 
formation at the site of application that can be resected to allow for 
longer follow-up of metastatic lesions (8). 
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Statement of Purpose 
 
Hypothesis  
Loss of E-cadherin plays an important role in melanoma formation and 
metastasis.  
 
Specific Aim 1: Determine the role of E-cadherin in melanoma formation. 
We will utilize the Tyr::CreERT mice that we generated and E-cadherinlox 
mice (39) to conditionally inactivate E-cadherin following 4-HT-induced 
Cre-mediated recombination.  We will inactivate E-cadherin specifically in 
melanocytes in both newborn and adult mice and evaluate effects on 
melanocyte proliferation and survival at several time points (0, 3, 7, 21, 60, 
and 360 days following recombination). 4-HT-treated Tyr::CreERT mice will 
be used as controls for these experiments.  We will determine if loss of E-
cadherin in melanocytes is sufficient to induce melanoma by following a 
cohort of 10 mice for 1 year that have undergone E-cadherin 
recombination as newborns.  These mice will be monitored daily for tumor 
growth.  Based on experience with other mouse models of melanoma, it is 
likely that additional genetic hits will be required to determine if E-
cadherin loss can contribute to melanoma formation.  We will cross mice 
to generate the following treated cohorts: E-cadherin loss with Braf 
activation and E-cadherin loss with Pten loss.   
 26 
Specific Aim 2: Determine the effect of E-cadherin loss on epithelial-
mesenchymal transition (EMT). 
We will evaluate the effect of inactivation of E-cadherin on cellular 
morphology, migration, and expression of markers of epithelial-
mesenchymal transition in vivo.  E-cadherin has been proposed to be a 
downstream effector in the process of EMT; however, a reciprocal 
relationship has been demonstrated between E-cadherin re-expression in 
melanoma cell lines and subsequent down regulation of N-cadherin (41).  
We will examine whether loss of E-cadherin is sufficient to induce 
additional markers of EMT.  In particular, we will determine protein levels 
on the skin tissues generated in Specific Aim 1 by western blotting of E-
cadherin, N-cadherin, Vimentin, and Slug in lysates.  In addition, we will 
perform unbiased gene expression analyses (Affymetrix GeneChip Mouse 
Gene 1.0 ST Arrays) in order to determine the gene set that is upregulated 
and downregulated by inactivation of E-cadherin and specifically 
examine markers associated with EMT.  
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Specific Aim 3: Determine the effect of E-cadherin loss on melanoma 
metastasis. 
In order to determine the effect of E-cadherin on melanoma metastasis, 
we will induce E-cadherin loss in the setting of Braf activation, Pten loss, 
and Braf activation and Pten loss.  These models have different 
endogenous propensities for tumor formation and metastasis that may be 
uniquely modified by E-cadherin loss.  From previously published work by 
the Bosenberg lab, we know that Braf activation with Pten loss results in 
exuberant tumor formation without a clear latency and with bulky lymph 
node metastases within weeks of induction.  Isolated tumor cells are 
present in the lung (8).  We will carefully evaluate mice in these cohorts for 
extent and character of metastatic disease and any alterations in these 
phenotypes that E-cadherin loss causes.  In addition to these "metastasis" 
cohorts, we will carefully evaluate any mice for metastases from Specific 
Aim 1 that form tumors following inactivation of E-cadherin and Braf 
activation or inactivation of E-cadherin and Pten.  
 
We will evaluate the histology of primary and metastatic melanomas 
carefully to determine if there is an increase in the mesenchymal 
characteristics of tumorigenic cells, including a more spindled 
appearance, greater extent of invasion at the leading edge of the tumor, 
and increases in local lymphovascular invasion.  We expect that E-
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cadherin will alter the characteristics of both the primary melanomas and 
metastases; however, it is unclear if the extent of metastasis will be altered 
or if the sites will be altered.   
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Methods 
 
Work was completed by the following investigators:  
Lara E. Rosenbaum (LER), William Damsky (WD), Katrina Meeth (KM) 
 
Mouse strains and activation of Tyr-CreER 
Responsible investigators:  Breeding, genotyping and general 
maintenance of the mouse colony was completed by WD and LER, with 
WD being primarily responsible for the Braf E-cadherin cohort and E-
cadherin cohort and LER primarily responsible for the Braf Pten, Pten E-
cadherin and Braf Pten E-cadherin cohorts presented here.  
 
The Tyr-CreER, Braf, Pten and E-cadherin mouse strains were genotyped 
and assayed for recombination as previously described (37), (42), (43), 
and (39).  All strains were on a mixed background of C57BL/6, FVB and 129 
mice.  For tumor inductions, 4-hydroxytamoxifen (4-HT) (#H6278, 70% Z-
isomer from Sigma-Aldrich) was dissolved in dimethylsulfoxide (DMSO) to a 
concentration of 50 mg/ml.  For perinatal inductions, this 4-HT solution was 
applied with a small paintbrush (enough to wet the skin) to the belly of the 
mouse on postnatal days 3, 5 and 7.  For localized tumor inductions, a 
mouse was selected at postnatal day 21 and the hair between the 
shoulder blades was removed with a topical depilatory.  Next, 1 µl of 4-HT 
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at 8.3 mg/ml (dissolved in 1 part DMSO and 5 parts Ethanol) was directly 
applied to the skin of the mouse in the hairless area.  All experiments 
involving animals were reviewed and approved by the Yale Institutional 
Animal Care and Use Committee (IACUC). 
 
Immunohistochemistry and western blotting 
Responsible investigators:  Immunohistochemistry was completed by KM.  
Western blotting was completed by LER and KM.   
 
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded tumor sections.  Slides were processed using Vectastain 
peroxidase kit (Vector, #PK-4000) and developed with a 3, 3’-
diaminobenzidine (DAB) substrate kit (Vector, #PK-4100), according to the 
manufacturer’s instructions. 
 
Western blotting was performed using standard methods on uncultured, 
macrodissected tumor protein lysates.  
 
The protein detection in the immunohistochemistry and western blotting 
was accomplished with the following purchased antibodies:  
 
From Cell Signaling Technology: phospho-4E-BP1 (Thr37/46) (#2855), Actin 
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(#4970), Total Akt (#9272), phospho-Akt (Thr308) (#2965), phospho-Akt 
(Thr450) (#9267), phospho-Akt (Ser473) (#4060), E-cadherin (#3195), 
phospho-p70 S6 kinase (Thr389) (#9205), Total S6 ribosomal protein 
(#2217), phospho-S6 (Ser235/236) (#4858), and Slug (#9585).   
 
From Abcam: phospho-SGK1 (Ser422) (#ab55281) and Vimentin 
(#ab92547).   
 
From Millipore: N-cadherin (#04-1126).  
 
RNA purification and expression analysis 
Responsible investigator:  RNA purification and expression analysis were 
completed by LER.  
 
Total RNA was extracted from homogenous portions of macrodissected 
uncultured tumors using an RNeasy Mini kit (Qiagen) and eluted in the 
presence of Rnase inhibitor (Promega).  RNA was quantified and 
prepared per the University of Vermont Cancer Center Microarray Facility 
standards.  Quality was assessed by the facility with an Agilent 2100 
Bioanalyzer.  Samples were hybridized to GeneChip Mouse Gene 1.0 ST 
Arrays (Affymetrix). 
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Analysis of lymph node metastases 
Responsible investigator:  Data collection and analysis performed by LER. 
 
Lymph nodes (cervical, axillary, brachial, and inguinal) were formalin-
fixed, paraffin-embedded and sections were stained with hematoxylin 
and eosin (H&E).  Images of each lymph node were digitally captured 
and manually analyzed using Adobe Photoshop Creative Suite 5. 
 
Quantification of lung metastases 
Responsible investigator:  Method development, data collection and 
analysis were performed by LER.  
 
Lung lobes were individually separated and rinsed in PBS at room 
temperature.  Each lobe was mounted to a glass slide with Permount and 
coverslip and allowed to dry for 24 hours.  Low and high power 
microscopic images were obtained with a Vectra microscope from 
Cambridge Research & Instrumentation (CRi) and digitally captured with 
inForm software.  Each high power image was manually assessed for the 
presence or absence of melanoma metastases.  This method was 
developed (by LER) to be able to assess metastases not visible under a 
dissecting microscopic and to allow for a more rigorous assessment of 
each lung lobe.   
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Statistical analyses 
Responsible investigator:  Statistical analyses were completed by LER. 
 
Prism statistical analysis software was used for all analyses.  Kaplan-Meier 
survival curves were constructed and significance was determined using 
the Log-rank (Mantel-Cox) test.  For comparison of pooled data with two 
groups, unpaired t tests were used to determine significance. 
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Results 
LOSS OF E-CADHERIN IN THE BRAF/PTEN TUMOR MODEL 
In order to assess the role of E-cadherin in melanoma progression and 
metastasis, we first examined its loss in the context of the well-
characterized Braf/Pten tumor model.  This model, previously published in 
Nature Genetics in 2009, utilizes the Tyrosinase-CreERT system and 
engineered loxP sites in the genes for Braf and Pten (8). When 4-
hydroxytamoxifen (4-HT) is applied to the mouse, these genes are altered 
specifically in melanocytes, resulting in activation of Braf and loss of Pten.  
These genetic changes result in melanoma in 100% of mice that is lethal in 
approximately 30-40 days with metastases to the lymph nodes and lungs.   
 
Two different modes of tumor induction have been developed.  The first, 
henceforth referred to as perinatal induction, involves applying 4-HT 
topically on days 3, 5, and 7 of life leading to systemic absorption and 
genetic recombination in effectively all melanocytes on the mouse.  The 
second method of tumor induction, called local induction, requires a 
small volume of 4-HT applied once to a small area of skin on the mouse, 
leading to genetic recombination in just that local area.  This method of 
local induction allows for a single tumor nodule to grow.  Per the 
approved animal protocol utilized here, mice were euthanized when the 
tumor reached 1 cm3 in size.  
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Decreased Survival with Loss of E-cadherin 
These two methods were utilized to assess tumor growth and 
development in the context of loss of E-caderin.  The comparison groups 
focused on in this section are the Braf/Pten inducible mice versus 
Braf/Pten mice with inducible, melanocyte-specific loss of E-cadherin 
(Braf/Pten/Ecad model) (Figure 1).  As shown here, comparisons with both 
the perinatal induction (Figure 1A) and the local induction (Figure 1B) 
show a quicker progression to lethality in the Braf/Pten/Ecad group 
compared to the Braf/Pten group (p=0.024 [perinatal induction] and 
p=0.043 [local induction]).   
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Figure 1. Kaplan-Meier survival curves for Braf/Pten/Ecad cohorts vs. 
Braf/Pten cohorts.  (A) Perinatal induction protocol and (B) Local 
induction protocol. 
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No Difference in Gross Phenotype 
By inspection, there are no gross differences in the melanomas formed in 
the Braf/Pten/Ecad tumor model compared to the Braf/Pten tumor model 
(Figure 2).  In both cases, the mice become covered in darkly pigmented 
confluent melanoma (perinatal induction) (Figure 2A), including over their 
peri-oral skin (Figure 2B) and footpads (Figure 2C).   
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Figure 2. Gross phenotype (perinatal induction) of representative mice.  
(A) Whole mouse, (B) Peri-oral skin, and (C) Footpads. 
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Metastasis to the Lymph Nodes and Lungs 
The next important assessment was to determine the pattern of 
metastases in the Braf/Pten/Ecad cohort compared to the Braf/Pten 
cohort.  In both cohorts, metastases to the lymph nodes were assessed 
and quantified from perinatally induced mice (Figure 3).  Both cohorts 
showed clear metastases to the lymph nodes both macroscopically and 
histologically (Figure 3A and 3B).  When the area of lymph node involved 
with melanoma was quantified from the hematoxylin and eosin (H&E) 
slides, there was no difference in the amount of melanoma in each lymph 
node (p=0.28) (Figure 3C).    
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Figure 3. Metastases to the Lymph Nodes.  Metastases to the lymph 
nodes can be seen (A) macroscopically and (B) histologically, stained 
by hematoxylin and eosin (H&E).  (C) Quantification of the area of 
lymph node involved with melanoma. 
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Additionally, metastases to the lungs were assessed in the two perinatally 
induced cohorts (Figure 4).  The number of lung metastases was 
quantified by a newly developed pressed lung technique.  This technique 
allowed for visualization of microscopic metastases that are not easily 
detected by other means (Figure 4A).  These metastases were quantified 
per lobe of lung and there was no difference between the two cohorts 
(p=0.39) (Figure 4B).   
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Figure 4. Metastases to the Lungs.  Entire lung lobes were digitally 
captured under a light microscope and assessed for the presence of 
metastases.  (A) Representative lung metastasis.  (B) Quantification of 
lung metastases per lobe in each cohort. 
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Assessment of mTOR Activity 
While both cohorts were expected to show significant mTOR activity due 
to the engineered loss of Pten, it was important to assess for any changes 
in activity of either mTORC1 or mTORC2 with concomitant loss of E-
cadherin.  This goal was accomplished through western blotting of tumor 
protein lysates from representative samples of the two cohorts (Figure 5).  
Several downstream targets of mTOR were assessed.  For mTORC1 activity, 
levels of phospho-4E-BP1 (Thr 37/46) and phospho-S6 ribosomal protein 
(Ser235/236) were assessed along with total levels of S6 ribosomal protein 
for comparison (Figure 5A).  These threonine and serine residues on 4E-BP1 
and S6, respectively, are known targets of mTORC1 and thus serve as a 
proxy for the level of mTORC1 activity in these tumors.  For mTORC2 
activity, levels of phospho-SGK1 (Ser422) and phosphor-Akt (Ser473) were 
assessed along with total Akt levels (Figure 5B).  These serine residues are 
known targets for mTORC2 and thus correlate with mTORC2 activity.  From 
this data there are no clear differences in either mTORC1 or mTORC2 
activity in the Braf/Pten/Ecad tumors compared to the Braf/Pten tumors.  
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Figure 5. Assessment of mTOR activity.  Western blotting was performed 
on Braf/Pten/Ecad and Braf/Pten tumor lysates as well as control skin 
lysate (Skin) and melanocyte lysate (Mel).  (A) mTORC1 activity was 
assessed by probing for phospo-4E-BP1 (Thr37/46) and phospho-S6 
ribosomal protein (Ser235/236), with total S6 ribosomal protein and actin 
controls.  (B) mTORC2 activity was assessed by probing for phospho-
SGK1 (Ser422) and phospho-Akt (Ser473), with total Akt and actin 
controls.  
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Markers of EMT 
Finally, loss of E-cadherin is predicted to allow for EMT to occur.  To assess 
for markers of EMT, RNA extracted from each of the tumor cohorts was 
probed and quantified using a mouse gene microarray.  This data was 
mined for markers of EMT, and RNA expression levels of these markers for 
the Braf/Pten/Ecad were compared to expression levels in the Braf/Pten 
cohort (Table 1).  These markers fell into two broad categories: 
transcription factors and structural proteins.  While several of the 
transcription factors and structural proteins that are predicted to be 
upregulated following an EMT were indeed upregulated (Slug, Twist2, 
Zeb1, N-cadherin and Fibronectin), others were equally expressed in the 
two tumor cohorts (Snail, Twist1, Zeb2, Hif1α and Vimentin).  Notably, one 
protein expected to decrease following an EMT (Claudin 1) was 
significantly upregulated in the Braf/Pten/Ecad cohort.   
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Table 1. Microarray RNA expression levels of markers of EMT.   
Fold-change in expression of RNA transcipts within Braf/Pten/Ecad 
tumors (Samples 1 and 2) relative to Braf/Pten tumors. 
Transcription Factors 
Gene Protein Sample 1 Sample 2 
Snai1 Snail 1.2 1.1 
Snai2  Slug 5.6 9.6 
Twist1  Twist1 1.3 1.8 
Twist2 Twist2 3.1 2.3 
Zeb1 Zeb1 10.8 8.8 
Zeb2 Zeb2 1.6 1.7 
Hif1α Hif1α 0.8 0.6 
Structural Proteins 
Cdh2 N-cadherin 4.9 8.6 
Vim Vimentin 1.2 1.3 
Fn1 Fibronectin 4.4 5.4 
Cldn1 Claudin 1 14.5 24.7 
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A NOVEL MOUSE MODEL: BRAF ACTIVATION AND LOSS OF E-CADHERIN 
While the Braf/Pten/Ecad melanoma model allowed for analysis of 
metastasis and markers of EMT compared to the previously characterized 
Braf/Pten model (8), it was important to evaluate E-cadherin loss in a 
system with fewer genetic changes to assess for its role in melanoma 
formation.  With that goal in mind, cohorts of mice were generated with 
the same inducible melanocyte-specific system using the perinatal 
induction protocol.  The cohorts generated included loss of E-cadherin 
only (Ecad model), Braf activation and loss of E-cadherin (Braf/Ecad 
model), and loss of E-cadherin and loss of Pten (Pten/Ecad model).  From 
the previously published study on the Braf/Pten model, we also have data 
for a cohort with Braf activation only (Braf model), a cohort with Pten loss 
only (Pten model) and of course the data from the Braf/Pten cohort (8).  
Together, these cohorts represent all possible permutations of these three 
genetic changes (except for the Braf/Pten/Ecad tumor model described 
in the previous section).    
 
Braf Activation with Loss of E-cadherin Leads to Melanoma Formation 
The Kaplan-Meier survival curves for all of the above-mentioned cohorts 
were generated and followed until death or at least 1.5 years (Figure 6).  
Examining these cohorts led to the discovery that Braf activation in 
combination with E-cadherin loss leads to melanoma formation in 100% of 
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the mice with tumor death occurring after an average of 302 days 
(range: 199 – 395 days) or approximately 10 months.  This finding is in 
striking contrast to the Braf/Pten tumor model, which has an average 
lifespan of 40 days (Figure 1, perinatal induction).  Mice with loss of E-
cadherin only, loss of Pten only or Braf activation only show no tumor 
formation for 1.5 or more years.  Additionally, the Pten/Ecad model shows 
no tumor formation for an average of 720 days (range: 641 – 884 days) or 
approximately 2 years.  The Braf/Ecad tumor model when compared to 
the other tumor models individually (none of which develop tumors) is 
statistically significant with p<0.0001 for all comparisons.  Additionally, the 
Braf/Ecad tumor model is statistically different from the Braf/Pten tumor 
model (p<0.0001).    
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Figure 6. Kaplan-Meier survival curves for Braf/Ecad cohorts vs. Braf, 
Pten, Ecad and Pten/Ecad cohorts.  There is a statistically significant 
difference (p<0.0001) between the Braf/Ecad cohort and all other 
cohorts shown here.  
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Assessment of mTOR Activity and Markers of EMT 
In order to assess the functional changes that occurred within the 
Braf/Ecad tumor model, western blotting was performed to investigate 
mTOR activity as well as markers of EMT (Figure 7).  First, mTORC1 activity 
was assessed by looking at downstream targets, including phospho-4E-BP1 
(Thr 37/46), phospho-S6 ribosomal protein (Ser235/236), and phospho-p70 
S6 kinase (Thr389) (Figure 7A).  From this data, there is evidence of 
mTORC1 activity in the Braf/Ecad tumors, though somewhat decreased 
compared to the Braf/Pten tumors.  While there is less phosphorylation of 
S6 ribosomal protein in just one out of three Braf/Ecad tumors, there is 
decreased phosphorylation of both p70 S6 kinase and 4E-BP1 in all 
Braf/Ecad tumors compared to Braf/Pten tumors. 
 
Next, mTORC2 activity was assessed by looking at levels of phospho-SGK1 
(Ser422) and phospho-Akt (Ser473) (Figure 7B).  Additional phosphorylation 
sites on Akt (Thr450 and Thr308) were also examined (Figure 7B).  These 
three Akt phosphorylation sites (Thr308, Ser473, and Thr450) all correspond 
to activation of Akt.  While one of the Braf/Ecad tumors has elevated 
levels of phospho-SGK1 (Ser422) suggesting the possibility of elevated 
mTORC2 activity, this is not consistent across the other two Braf/Ecad 
tumors nor is it consistent when looking at phospho-Akt (Ser473), another 
marker of mTORC2 activity.  By examining the three phospho-Akt blots, 
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there is a trend toward decreased, though present, phosphorylation of 
Akt in the Braf/Ecad tumors compared to the Braf/Pten tumors.  This result 
suggests that Akt is active in the Braf/Ecad tumors, but less so than in 
Braf/Pten tumors.   
 
Finally, it is important to investigate whether or not an EMT has occurred 
within the Braf/Ecad tumors.  To assess this, tumor lysates were probed for 
E-cadherin, N-cadherin, Slug, and Vimentin (Figure 7C).  If an EMT has 
occurred, one would predict decreased or no E-cadherin, increased N-
cadherin (termed “cadherin-switching” to explain the “switch” from E-
cadherin to N-cadherin), increased Vimentin (an intermediate filament 
found in mesenchymal cells) and increased Slug (a transcription factor 
that downregulates expression of E-cadherin).  In the Braf/Ecad tumor 
lysates the first important aspect to note is that two of the lysates contain 
E-cadherin.  This finding is due to contamination of the tumor lysate from 
overlying skin, which strongly expresses E-cadherin (as can clearly be seen 
in the skin lysate control) and not due to expression of E-cadherin in the 
tumors (which have been genetically-engineered to lack E-cadherin).  
Looking at the other structural proteins (N-cadherin and Vimentin), both 
the Braf/Ecad and Braf/Pten tumors express similar levels of these proteins.  
Interestingly, differences are found when examining expression levels of 
Slug.  There are wide variations in expression level when looking at the 
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three Braf/Ecad tumors, from none to slight to high, while the Braf/Pten 
tumors consistently show moderate expression of Slug.  The variation in 
expression levels in the Braf/Ecad tumors is not entirely surprising, as these 
tumors have a long latency period with a wide range, suggesting there 
might be stochastic variation within these tumors.  This observation is in 
contrast to the Braf/Pten tumor model, which has a short latency period 
for tumor development and thus, little variability in protein expression.   
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See previous page for figure. 
 
Figure 7.  mTORC1/2 activity, Akt activity and markers of EMT. Western 
blotting was performed on Braf/Ecad and Braf/Pten tumor lysates as 
well as control skin lysate (Skin) and melanocyte lysate (Mel).  (A) 
mTORC1 activity was assessed by probing for phospo-4E-BP1 (Thr37/46), 
phospho-p70 S6 kinase (Thr389) and  phospho-S6 ribosomal protein 
(Ser235/236), with total S6 ribosomal protein and actin controls. (B) 
mTORC2 activity was assessed by probing for phospho-SGK1 (Ser422) 
and phospho-Akt (Ser473).  Akt activity was additionally assessed with 
phospho-Akt (Thr450) and phospho-Akt (Thr308).  Total Akt and actin 
controls are shown.  (C) Markers of EMT include E-cadherin, N-caderin, 
Slug, and Vimentin, with an actin control. 
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As was previously established by the Bosenberg lab (8), activation of Braf 
alone in melanocytes does not lead to melanoma formation but does 
lead to nevi formation in 100% of mice.  To further understand the 
formation of tumors in the Braf/Ecad cohort, immunohistochemistry (IHC) 
was performed on Braf/Ecad tumors and compared to IHC performed on 
Braf/Pten tumors as well as these Braf-activated nevi (Figure 8).   
Braf/Ecad tumors were probed for E-cadherin (to definitively show the 
genetically engineered loss) as well as Vimentin (Figure 8A).  A 
representative hematoxylin and eosin (H&E) slide of a Braf/Ecad tumor is 
also shown.  It is worth noting that the Braf/Ecad tumor contains no E-
cadherin, as expected, but that the overlying epidermis shows clear, 
strong E-cadherin staining.  Vimentin is strongly expressed in the Braf/Ecad 
tumor.   
 
To further establish mTORC1 activity in the Braf/Ecad tumors, IHC was 
performed with phospho-S6 ribosomal protein (Ser235/236) antibody 
(Figure 8B).  This conclusively shows that mTORC1 is active in the Braf/Ecad 
tumors at a similar level to that of Braf/Pten tumors and significantly 
increased from Braf nevi.  Additionally, the intensity of 
immunohistochemical staining for mTORC2 substrates, including phospho-
Akt (Ser473) and phospho-SGK1 (Ser422), was moderate and essentially 
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equal in Braf/Ecad tumors and Braf/Pten tumors and was greater than 
that seen in Braf nevi (data not shown).   
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Figure 8. Markers of EMT and mTORC1 activity in Braf/Ecad tumors.  
Immunohistochemistry was performed on Braf/Ecad tumors, Braf/Pten 
tumors and nevi from mice with Braf activation alone.  (A) Braf/Ecad 
tumors were stained with H&E and also probed with antibodies to E-
cadherin and Vimentin.  (B) Braf/Ecad tumors, Braf/Pten tumors and 
Braf nevi were probed for phospho-S6 ribosomal protein (Ser235/236) (a 
marker of mTORC1 activity). 
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Microarray Analysis of EMT 
Finally, RNA microarray analysis was used to assess for markers of EMT 
within the Braf/Ecad tumors and compared to the Braf/Pten tumors (Table 
2).  As discussed previously, these markers fell into two broad categories: 
transcription factors and structural proteins.  While several of the 
transcription factors and structural proteins that are predicted to be 
upregulated following an EMT were indeed up-regulated (Slug, Zeb1, N-
cadherin and Fibronectin), others were equally expressed in the two 
tumor cohorts (Snail, Twist1, Twist2, Zeb2, Hif1α and Vimentin).  Notably, 
one protein expected to decrease following an EMT (Claudin 1) was 
significantly upregulated in the Braf/Ecad cohort.  These data are quite 
similar to that seen the Braf/Pten/Ecad cohort (Table 1).   
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Table 2. Microarray RNA expression levels of markers of EMT.   
Fold-change in expression of RNA transcipts within Braf/Ecad tumors 
(Samples 1 and 2) relative to Braf/Pten tumors. 
Transcription Factors 
Gene Protein Sample 1 Sample 2 
Snai1 Snail 1.0 0.8 
Snai2  Slug 14.9 12.4 
Twist1  Twist1 1.2 2.4 
Twist2 Twist2 0.9 1.2 
Zeb1 Zeb1 12.8 11.5 
Zeb2 Zeb2 1.5 1.6 
Hif1α Hif1α 0.4 0.6 
Structural Proteins 
Cdh2 N-cadherin 25.3 18.1 
Vim Vimentin 1.5 1.4 
Fn1 Fibronectin 10.9 5.7 
Cldn1 Claudin 1 49.5 10.5 
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Discussion 
This work investigates the role of E-cadherin loss in melanoma formation 
and metastasis and its role in EMT.  Few investigators have assessed E-
cadherin in such a controlled manner in an in vivo immunocompetent 
model.  Two primary models were assessed here, that of Braf/Pten/Ecad 
and the newly discovered Braf/Ecad model, but other genetic contexts 
utilizing this melanocyte-specific inducible loss of E-cadherin could also be 
developed in future work.   
 
Interestingly, in the Braf/Pten/Ecad tumor model one would have 
predicted an increase in metastases with possible concomitant increase 
in mortality.  While the Braf/Pten/Ecad tumor model does show a 
decreased lifespan compared to the Braf/Pten tumor model, there are no 
clear phenotypic differences between the two models and there is no 
change in the metastatic potential.  This finding suggests that if loss of E-
cadherin leads to increased metastasis, it is contingent on genetic 
context.  While it is not clear why there is a decreased lifespan in this 
cohort, changes in mTORC1/2 do not account for any differences 
between these two models. Future investigation into tumor growth rates 
and other mechanistic changes may shed light on these questions.   
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The discovery that Braf activation in combination with loss of E-cadherin 
was sufficient to produce melanoma in 100% of mice is somewhat 
surprising, but may have been predictable due to the suggested role of E-
cadherin as a tumor suppressor and increasing evidence that loss of E-
cadherin leads to activation of the PI3K/Akt pathway (19) (20) (21).  This 
relationship, however, is challenging to so clearly illustrate in 
epidemiologic or in vitro studies but is readily apparent in the melanoma 
tumor model developed here.  Mechanistic studies investigating the 
Braf/Ecad tumors reveal activation of Akt, as well as both mTORC1 and 
mTORC2, supporting the idea that loss of E-cadherin leads to activation of 
the PI3K/Akt pathway in an in vivo immunocompetent cancer model.  As 
shown previously with the Braf/Pten tumor model (8), Braf activation with 
activation of the PI3K/Akt pathway (in this model due to loss of Pten) is 
synergistic and sufficient for melanoma formation in 100% of mice.  The 
same mechanism appears to be important in the development of tumors 
in the Braf/Ecad model, though stochastic changes are likely to also play 
a significant role given the long latency period of tumor development.   
 
Finally, it is important to address the question of whether or not E-cadherin 
induces an EMT.  There were some markers of EMT that were upregulated 
in both the Braf/Pten/Ecad cohort and the Braf/Ecad cohort relative to 
Braf/Pten tumors.  However, RNA levels of other markers were unchanged.  
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Importantly though, loss of E-cadherin did not lead to wildly enhanced 
metastasis (in either genetic context), suggesting that while some events 
characteristic of an EMT did occur (as shown by the microarray data), 
these events were not sufficient for increased metastasis.  In reality, there is 
likely a hybrid state that occurs in vivo, in so far as both mesenchymal and 
epithelial markers are expressed in the highly abnormal dysregulated 
cancer cell.   
 
Within the study of E-cadherin and tumor metastasis, some investigators 
believe that release of β-catenin is the key downstream mechanism 
leading to the molecular changes and metastatic potential of cells 
lacking E-cadherin.  While β-catenin was not directly addressed in this 
study, it has been definitively addressed by Damsky et al. with a mouse 
model also developed in the Bosenberg lab (44).  In this study, β-catenin 
was both stabilized and knocked-out in an inducible manner and specific 
to melanocytes in the context of Braf activation and loss of Pten.  The 
model that included β-catenin stabilization, Braf activation and Pten loss 
(Braf/Pten/β-cat-STA) showed a remarkable increase in the number of 
metastases to the lungs as well as to the spleen and bowel.  This 
phenotype is in stark contrast to that of the Braf/Pten/Ecad and Braf/Ecad 
models and supports the idea that the functional changes within the cells 
of these tumors from loss of E-cadherin are not simply due to changes of 
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expression of β-catenin.  Additionally, the tumors formed in the 
Braf/Pten/β-cat-STA tumor model, despite being highly metastatic, 
actually showed an increased level of E-cadherin expression.   
 
While the work completed here further enhances the understanding of 
the role of E-cadherin in melanoma formation and metastasis, more work 
will need to be done to further understand the complexities of tumor 
formation and spread.  While loss of E-cadherin can play a substantial role 
in melanoma formation as shown in the Braf/Ecad tumor model, its role in 
EMT and metastasis is more complex and likely highly dependent on 
genetic context.  The Braf/Pten/Ecad tumor model did not show an 
increase in metastases and the Braf/Pten/β-cat-STA model (44) shows a 
remarkable increase in metastases but also with increased E-cadherin 
expression.  Additional genetic combinations will need to be investigated 
to further understand the role of E-cadherin in melanoma formation and 
metastasis.  With better understanding, new treatments will be developed 
to help manage this devastating cancer.   
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